Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up
Edgard Ferreira de Araújo1, Eduardo Gregório Chamlian2, Alexey Pomares Peroni2
1Centro Cardiológico de Salinas, Salinas, MG, Brasil.
Insights
Cardiac resynchronization therapy significantly improves New York Heart Association class and survival in patients with Chagas cardiomyopathy and heart failure. This treatment offers a promising outcome for advanced disease stages.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Technology
Background:
- Chagas disease is a significant cause of cardiomyopathy and sudden death.
- High mortality is observed in patients with New York Heart Association (NYHA) class IV heart failure due to Chagas cardiomyopathy.
Purpose of the Study:
- To analyze the clinical outcomes of patients with Chagas cardiomyopathy and congestive heart failure.
- To evaluate the effectiveness of cardiac resynchronization therapy (CRT) combined with optimized pharmacological treatment.
Main Methods:
- A cohort of 72 patients with Chagas cardiomyopathy (NYHA class III and IV) received CRT between 2004 and 2009.
- Clinical evolution was monitored, and statistical analysis (t-test, Wilcoxon test) was performed with a significance level of P < 0.05.
Main Results:
- After an average follow-up of 46.6 months, 87.4% of patients improved to NYHA class I or II (P<0.001).
- Therapy response was observed in 65.3% of patients (P<0.001), with an overall mortality rate of 34.7%.
Conclusions:
- Cardiac resynchronization therapy leads to significant improvements in NYHA class for chronic Chagas cardiomyopathy patients.
- The therapy also resulted in increased left ventricle ejection fraction, reduced ventricular volumes, and improved patient survival.
Introduction:
Chagas disease is a major cause of cardiomyopathy and sudden death in our country. It has a high mortality when their patients develop New York Heart Association (NYHA) class IV.
Objective:
The objective of this study is to analyze the clinical outcome of patients with Chagas' cardiomyopathy with congestive heart failure with optimized pharmacological therapy, undergoing cardiac resynchronization therapy.
Methods:
Between January 2004 and February 2009, 72 patients with Chagas' cardiomyopathy in NYHA class III and IV underwent cardiac resynchronization therapy and were monitored to assess their clinical evolution. We used the t test or the Wilcoxon test to compare the same variable in two different times. A P value < 0.05 was established as statistically significant.
Results:
The average clinical follow-up was 46.6 months (range 4-79 months). At the end of the evaluation, 87.4% of patients were in NYHA class I or II (P<0.001). There was response to therapy in 65.3% of patients (P<0.001), with an overall mortality of 34.7%.
Conclusion:
In patients with chronic Chagas cardiomyopathy undergoing cardiac resynchronization therapy, we found the following statistically significant changes: improvement in NYHA class and increase of left ventricle ejection fraction, a decrease of the systolic final diameter and systolic final left ventricle volume and improvement of patient survival.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Endocarditis III: Medical Management


